Abstract:Liver Transplant Centre, Department of General Surgery, Huashan Hospital, Fudan University. Introduction: Hepatocellular carcinoma (HCC) is an increasingly common indication for liver transplantation (LT), while post-transplant HCC recurrence is the main problem affecting progonosis of recipients. From 2014 to 2019, HCC was the indication for 45% of liver transplant registrants in our center, as the most common reason for LT. Post-transplantation preventive measures including the immunosuppression regimen like sirolimus, and immunotherapies like sorafenib and lenvatinib. In this study, we aimed to explore the effects of sirolimus (SRL)/tacrolimus (TAC) and sorafenib/lenvatinib in preventing recurrence. Materials and Methods: This retrospective study including 207 recipients of liver transplants for hepatocellular carcinoma in Huashan hospitals affiliated to Fudan university. All recipients were followed up until December 2019 or until recurrence. The inclusion criteria: 1) histologically proven to be HCC; 2) without major vascular invasion. The exclusion criteria: 1) concurrent malignancy; 2) died within 3 months; 3) other malignancies. The baseline organ recipients’ demographic characteristics including age, sex, and transplant outcomes including cancer-related mortality. For groups, we constructed Kaplan-Meier curves to estimate overall survival proportions and cumulative incidence curves. All recipients received tacrolimus in their initial immunosuppressant regimen, and part of those received sirolimus in the long term regimen.Results and Discussion: Between 2014 and 2019, 207 liver recipients remained in our study population with a follow-up starting 3 months after transplantation (maximum follow-up of 5 years). Among these recipients, 78 (37.7%) received SRL in their long-term immunosuppressant regimen, 71(34.3%) received lenvatinib and most of recipients are beyond Milan criteria. In total, there were 69 recurrences and 32 cancer-related deaths. HCC recurrence rates was similar in sirolimus users and non-users in the In-Milan criteria, while appeared lower in sirolimus users compared with tacrolimus users in the Out-Milan criteria group. All recipients were clsssifed into six groups (SRL+ lenvatinib, TAC+ lenvatinib, SRL+ sorafenib, TAC+ sorafenib, SRL only, TAC only). The results show that especially in Out-Milan group, patients were benefied from TAC combined with lenvatinib effectively. Targeted therapies combined with sirolimus may bring a better prognosis among patients who do not meet the Milan criteria. Partly because of the limited data, the best combination of immunosuppression regimen and immunotherapies for different risky groups needs further study to be verified.Conclusion: In conclusion, immunosuppression and immune-targeted durgs are feasible measures for preventing HCC recurrence of recipients for HCC-transplantation. Intervention like modulating dose of SRL/TAC and sorafenib/lenvatinib may help patients prevent recurrence and receive a better long-term prognosis. References: 1. Yanik EL, Chinnakotla S, Gustafson SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2016; 22 (5): 627. 2. Verna EC, Patel YA, Aggarwal A, et al. Liver transplantation for hepatocellular carcinoma: Management after thetransplant. American journal of transplantation: official journal of the American Society ofTransplantation and the American Society of Transplant Surgeons 2020; 20 (2): 333. 3. Grigg SE, Sarri GL, Gow PJ, Yeomans ND. Systematic review with meta-analysis: sirolimus- or everolimus-basedimmunosuppression following liver transplantation for hepatocellular carcinoma. Alimentary pharmacology & therapeutics 2019; 49 (10): 1260. 4. Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in livertransplantation for hepatocellular carcinoma. Alimentary pharmacology & therapeutics 2013; 37 (4): 411. 5. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet (London, England) 2018; 391 (10127): 1301.

A randomized controlled trial of licartin for preventing hepatoma recurrence after liver transplantation

Efficacy of Licartin Combined with Transcatheter Hepatic Arterial Chemoembolization in the Treatment of Middle-Advanced Primary Liver Cancer.

Preliminary evaluation of immune checkpoint inhibitors as a salvage treatment of tumor recurrence after liver transplantation for hepatocellular carcinoma

Novel strategy of sirolimus plus thymalfasin and huaier granule on tumor recurrence of hepatocellular carcinoma beyond the UCSF criteria following liver transplantation: A single center experience

131 I-Labeled-Metuximab Plus Transarterial Chemoembolization in Combination Therapy for Unresectable Hepatocellular Carcinoma: Results from a Multicenter Phase IV Clinical Study.

Therapeutic Effect of Transarterial Licartin Infusion in Combination with Transcatheter Arterial Chemoembolization for Advanced Hepatocellniar Carcinoma

EFFECTS OF IMMUNOSUPPRESSION AND ADJUVANT IMMUNE-TARGETED DRUGS IN PREVENTING HCC RECURRENCE AFTER LIVER TRANSPLANTATION

Therapeutic Effectiveness of Liver Transplantation: a Single Center Study of 203 Consecutive Cases

Abstract 1456: the Safety and Efficacy of Lenvatinib in Preventing Early Recurrence after Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Single-Center, Retrospective, Propensity-Matched Study

Efficacy and Safety of Lenvatinib for Preventing Tumor Recurrence after Liver Transplantation in Hepatocellular Carcinoma Beyond the Milan Criteria

Molecular Markers and Hepatocellular Carcinoma: Lending a Helping Hand in Liver Transplantation?

AGH SCORE PREDICTS RECURRENCE AND RESPONSE TO ADJUVANT-TARGETED THERAPY IN HBV RELATED HCC AFTER LIVER TRANSPLANTATION

Analysis of factors influencing the distribution of 131-I in combined treatment of Licartin with transcatheter arterial chemoembolization in primary hepatic carcinoma

Pre-transplant Use of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Multicenter, Retrospective Cohort Study

Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience

Traditional Herbal Medicine in Preventing Recurrence after Resection of Small Hepatocellular Carcinoma: a Multicenter Randomized Controlled Trial

Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study

951P HAIC Combined with Anlotinib and TQB2450 As Adjuvant Therapy for Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence after Hepatectomy: A Single-Centre, Non-Randomised, Open Clinical Study

Role of selected criteria and preventive chemotherapy in tumor recurrence after liver transplantation

Liver Transplantation for Patients with Hepatocellular Carcinoma at the Liver Cancer Institute of Fudan University, China.

“No-Touch” Left Approach for Recipient Hepatectomy: A Promising Strategy to Minimize Hepatocellular Carcinoma Recurrence in Liver Transplantation